Nahum Wood’s Post

Part III: Exploring 2023's Breakthroughs: Phase 2 Oncology Clinical Trials Uncovered #clinicaltrials #oncology In this part, lets deep dive into Phase 2 oncology trials of 2023 which uncovers significant progress and insights, spotlighting the pharmaceutical industry's dedication towards addressing a wide range of cancer challenges. #AdvancedSolidTumor emerges as a primary focus, leading in the number of trials underscoring the industry’s commitment to comprehensive cancer care. The trials for #BreastCancer and #NonSmallCellLungCancer follow closely, reflecting precise endeavors to tackle some of the most widespread and lethal cancers, impacting millions globally. The diversity in research focus underscores a holistic approach to oncology, aiming to leave no stone unturned in the quest for cures.   But this data also prompts us to think beyond what's being researched. What are your thoughts on how can we leverage #emergingtechnologies to not only fill these gaps but also accelerate the path from trials to treatment?  Do let me know your insights and thoughts. #medicalinnovations #healthcaretrends #pharmaceuticalindustry #cancerresearch #clinicaltrials #medicalinnovation Source: www.clinicaltrials.gov

Summit Therapeutics, Inc. has completed enrolment for their Phase III HARMONi trial, which is great news for lung cancer patients! This trial is evaluating ivonescimab, combined with chemotherapy, for patients suffering from the challenging EGFR-mutated, locally advanced, or metastatic non-small cell lung cancer (NSCLC). Historically, this patient group has shown poor responses to existing PD-1 antibody treatments 💡 With the US FDA granting Fast Track designation, the development and review of this promising combination treatment can be accelerated. This ensures that we move closer to providing a much-needed solution for patients who have progressed on EGFR tyrosine kinase inhibitors (TKIs). Fast Track status allows for more frequent interactions and rolling review processes with the FDA, enabling quicker submissions and reviews of vital applications. The HARMONi trial's standout results will be anticipated mid-2025 - watch this space! #LungCancer #NSCLC #ClinicalTrials #ClinicalResearch #Biotechnology #SummitTherapeutics #LifeScience #StaffingPartner #ElixirAssociates

🌟Breaking Ground in Pancreatic Cancer Treatment in 2024 🌟 This year, pancreatic cancer leads in receiving FDA Orphan Drug Designations, reflecting an intensified focus on combating this formidable disease. Why does this matter? Our latest blog delves into the cutting-edge approaches being pioneered to fight pancreatic cancer, showcasing the role of innovative therapies and global efforts that make a difference. Discover how these advancements not only push the boundaries of medical science but also offer new hope to patients battling this aggressive cancer. Learn about the significant incentives and support facilitated by the FDA's ODD program, empowering developers to bring revolutionary treatments to market faster. 👉 Read more about these exciting developments and the future of pancreatic cancer treatment. https://wix.to/kQldTkr 🔗 Stay connected to get the latest insights on biopharmaceutical innovations and how they're transforming patient care. #PancreaticCancer #FDAOrphanDrug #Biopharma #InnovationInHealth #OrphanDrugDesignations #MedicalScience #HealthcareInnovation

Did you know that bladder cancer is the 6th most common type of cancer in the U.S., and over 80,000 people will be diagnosed this year? While there has been significant progress in developing new treatments, oncologists need better predictive biomarkers and tests that can inform the optimal treatment for individual patients. We’re advancing a multi-gene RNA expression test to guide the use of FGFR-targeted and other therapies to personalize bladder cancer treatment, so patients may achieve greater clinical benefit. Learn more about our FGFR-PRS test at https://bit.ly/3wms7Ta. #oncology #precisionmedicine #biotechnology #pharmaceuticals #RNAseq

🚀 Exciting Announcement from Axella Research! 🚀 We are thrilled to share that Mirror Biologics is starting up a new Phase 2 clinical trial in collaboration with Axella Research, focusing on advanced metastatic colorectal cancer (CRC). This trial, titled "COMUNITY" (NCT06557278), combines AlloStim® with an anti-PD-L1 therapy to potentially convert "cold" tumors into "hot" ones, making them responsive to immunotherapy. Key Details: -Target: Chemotherapy and immunotherapy-refractory MSS metastatic CRC patients. -Treatment: AlloStim® in combination with Bavencio (Avelumab). -Objective: To assess safety and efficacy as a fourth-line treatment. Estimated Enrollment: 50 participants. We invite investigators and clinical research sites interested in participating in this groundbreaking study to reach out to us for collaboration opportunities. email: trials@axellaresearch.com Stay tuned for updates as we advance in this critical research! #ClinicalResearch #Oncology #Immunotherapy #AxellaResearch #MirrorBiologics #ClinicalTrials #CancerTreatment

📣 Exciting times ahead in the realm of prostate cancer treatment! 👨🔬👩🔬 As we explore novel and emerging therapies, the future outlook appears promising. From targeted immunotherapies to precision medicine approaches, 📄 the landscape of prostate cancer care is rapidly evolving. Stay tuned for groundbreaking advancements that hold the potential to revolutionize patient outcomes. Together, we're shaping the future of prostate cancer treatment. For more informative updates, visit 🌐 www.vyuhpharma.com #PharmaRegulations #RegulatoryTrends #WhitePaper #PharmaceuticalIndustry #pharmanews #pharmaceutical #healthcare  #pharmaceuticalindustry #ProstateCancer #Innovation #MedicalAdvancements #CancerResearch #PrecisionMedicine #Immunotherapy #oncology

Day One Biopharmaceuticals has secured an exclusive license for DAY301 through a significant $1.2B deal with MabCare Therapeutics. This strategic partnership, fueled by a substantial $55M upfront investment, aims to transform the landscape of cancer therapy for individuals, both adults and children, challenged by solid tumors. 💊 DAY301 is an advanced antibody-drug conjugate (ADC) that targets PTK7 and has displayed potential as a first-in-class treatment for multiple cancer types, including esophageal, ovarian, lung, endometrial cancers, and pediatric cancers such as neuroblastoma. Having achieved FDA investigational approval, Day One is swiftly advancing towards phase 1 clinical trials.🩺 This collaboration represents a key step in expanding Day One's therapeutic portfolio and underscores our commitment to research that directly benefits those affected by cancer. #CancerResearch #Biotechnology #HealthcareInnovation

Our collaboration with Acrivon Therapeutics, Inc. continues to progress and create new hope for those affected by ovarian, endometrial, and bladder cancer. In case you missed it, the ACR-368 OncoSignature Assay, which incorporates Akoya’s PhenoImager HT instrument and multiplex immunofluorescence technology, was granted Breakthrough Device designation by the FDA in November. This designation highlights the potential of the assay, along with the Akoya technologies that underlie it, in identifying ovarian cancer patients who may benefit from treatment with ACR-368. Acrivon was additionally granted two Fast Track designations for the investigation of ACR-368 as a monotherapy last year. These designations are based on ACR-368 OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian and endometrial cancer. These Fast Track designations will expedite the development and regulatory review of ACR-368, facilitating its potential availability to patients in need. Learn how the ACR-368 OncoSignature Assay marks a significant advancement in identifying patients suitable for a targeted oncology agent, potentially ushering in a new era of precision medicine: https://bit.ly/45RVDvN #spatialbiology #precisionmedicine #spatialproteomics #oncology

In recent news... In the dynamic field of oncology, clinical trials are pivotal in shaping the future of cancer treatment. Today, we reflect on the recent findings regarding Merck's Keytruda and Bristol Myers Squibb's Opdivo, as reported by Fierce Pharma. Our heatmap analysis reveals the landscape of ongoing clinical trials in adjuvant Renal Cell Carcinoma, showcasing Keytruda (pembrolizumab) and Opdivo (nivolumab) at the forefront. Keytruda leads with a higher number of trials across phases 1, 2, and 3, indicating a strong presence in the research pipeline. Despite facing challenges, Opdivo remains a key player, with trials underway that reflect the commitment of BMS to advancing cancer care. This heatmap underscores the efforts of both Merck and BMS in the pursuit of innovative oncology therapies. As we share this news, we do so with an objective lens, recognizing the complexities of drug development and the dedication of all our partners in this journey. https://lnkd.in/ek5dGZpR . . . . . . #KogniticAInsights #Clinicaltrialintelligence #ClinicalTrials #Oncology #PharmaInnovation #Keytruda #Opdivo #Kognitic

Oncology clinical trials shape the future of cancer treatment. Recent findings on Keytruda and Opdivo have caught our attention. Our heatmap analysis highlights the landscape of ongoing clinical trials in adjuvant Renal Cell Carcinoma, revealing Keytruda and Opdivo as leaders in the space. Together we can find a cure!